Ocuphire Pharma Investor Day Presentation Deck

DR DME 22 APX3330 Product Candidate Profile for Multiple Retinal Indications First-In-Class Ref-1 Inhibitor with Favorable Human Safety Data APX3330: Well-tolerated Oral Dose up to 600mg/day Twice Daily Dosing Expected Efficacy Data Improving Eye Health in Diabetics Inflammation ↓ Abnormal Angiogenesis Enhance Compliance & Exposure Oral pill may reduce the burden of frequent anti-VEGF injections KO Phase 1 and Phase 2 clinical trials by Eisai and Apexian Few Systemic Adverse Effects < 5% Mild Gastrointestinal (diarrhea) < 5% Mild Skin Rash (reversible) No Significant Organ Toxicity: Liver ● ● ● ● Cardiovascular (BP, HR) Kidney Neurologic Pulmonary No Ocular Effects Favorable Safety Profile ● ● No observed ocular AEs Ocuphire PHARMA

View entire presentation